ada 2025 retatrutide results More data on dropped today at the conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the Phase Lilly's triple agonist achieves 16.8%
Description
Vomiting Often linked with nausea as the body adjusts to the medication
The dose of the drug can be increased to 1 mg, 2 mg, or 4 mg after 4 weeks, depending on the patients response
Imaging or endoscopy may be recommended when symptoms suggest underlying stomach disease
What About Drug Interactions
doi: 10.1016/S0022-2275(20)41151-4 61 GalsgaardKDPedersenJKnopFKHolstJJWewer AlbrechtsenNJ
Call (703) 865-6490 or visit novaphysicianwellness.com to request information or book a consultation online
